ClinicalTrials.gg
CompletedNCT00397293Updated Aug 24, 2010

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

A Phase 1/2 interventional study of AT-101 and topotecan in Small Cell Lung Cancer, sponsored by Ascenta Therapeutics. Completed at 19 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-08-24.

Sponsored by Ascenta Therapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing topotecan in Small Cell Lung Carcinoma — 2 open to participants now, 4 under way, 2 of them phase 3. Topotecan · Small Cell Lung Carcinoma.

Enrollment
16th of 28
36 · median 44
Started
2006
with 2 others
Phase 1/2
3 of 29
none open now
Registered
19th of 29
by date
Lead sponsor
1 of 29
Ascenta Therapeutics

Among the 29 studies testing topotecan in Small Cell Lung Carcinoma, this one is the 16th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2006, is one of 3 in phase 1/2, and was the 19th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 29 studies testing topotecan in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About topotecan

Topotecan: first FDA approval 1996 (HYCAMTIN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing topotecan in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This is an open label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with topotecan in relapsed/refractory small cell lung cancer

Read the detailed description

Further Study Details provided by Ascenta:

03

Conditions studied

  • Small Cell Lung Cancer

Keywords

  • AT101
  • AT-101
  • cancer
  • lung
  • small-cell
  • topotecan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed small cell lung cancer (SCLC). Mixed histology will not be eligible.
  • Progression of disease after only one prior platinum containing chemotherapy regimen. Prior Regimen must not have contained irinotecan
  • All patients must have .
  • Patients may have received prior radiation therapy but they must have recovered from all treatment-related toxicities.
  • performance status 0-1
  • Adequate hematologic function
  • Adequate liver and renal function
  • Ability to swallow oral medication

Exclusion criteria

Exclusion Criteria:

  • Patients with more than one prior regimen of chemotherapy or prior regimen that did not contain a platinum agent. Note: Patient who stopped prior therapy due to toxicity or had less than 2 cycles of platinum based therapy would not be eligible for the phase II portion of this study.
  • Prior chemotherapy regimen containing irinotecan.
  • Active secondary .
  • Unstable or progressive .
  • Prior history of radiation therapy to > 25% of the bone marrow.
  • Uncontrolled concurrent illness including, but not limited to: serious uncontrolled infection, symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.
  • Failure to recover from toxicities related to prior therapy (e.g., surgery, radiation, chemotherapy).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Interventions

  • DrugAT-101

    40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.

  • 40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events.

    Time frame: 13 months

Secondary outcomes

  1. complete or partial remission of disease

    Time frame: 16 months

07

Study locations

19 sites
  • Birmingham, Alabama 35233, United States
  • Hot Springs, Arkansas, United States
  • Loma Linda, California 92354, United States
  • Stamford, Connecticut, United States
  • Jacksonville, Florida, United States
  • Lake City, Florida, United States
  • Boston, Massachusetts 02114, United States
  • Rochester, Minnesota 55905, United States
  • Lebanon, New Hampshire, United States
  • High Point, North Carolina, United States
  • Portland, Oregon 97213, United States
  • Columbia, South Carolina, United States
  • Hilton Head Island, South Carolina, United States
  • Germantown, Tennessee, United States
  • Austin, Texas 78705, United States
  • Burlington, Vermont 05405, United States
  • Huntington, West Virginia, United States
  • Research Center (16)
    Russia, Russian Federation
  • Research Centers (8)
    Ukraine, Ukraine
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2006
First posted
Nov 9, 2006
Start
Nov 2006
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results delay requested
Aug 12, 2010
Last update
Aug 24, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00397293
Lead sponsor
Ascenta Therapeutics
First posted
Nov 9, 2006
Start date
Nov 2006
Primary completion
Dec 2008
Completion
Dec 2008
Last update
Aug 24, 2010

Study contacts

Lance Leopold, MD
study chair · Ascenta Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gossypol-acetic acid · Topotecan

Start the discussion